The trial’s primary efficacy endpoint is AF burden, which refers to the percentage of time a participant is in AF.

-- EUR35 million Series C funding to accelerate the clinical and industrial development of FlowMaker (R) -- EUR48 million in grants from the IPCEI Tech4Cure program to structure the European Active ...

I spoke with neuroscientists from an Incheon, Korea-based startup that's looking to minimize the symptoms of epilepsy or Parkinson's disease.

Senseonics Holdings, Inc. SENS recently reached an important commercialization milestone with the launch of its Eversense 365 ...

The US Food and Drug Administration (FDA) has granted 510 (k) clearance for BlueWind Medical, Ltd.’s enhanced Revi® implantable tibial neuromodulator for treatment of urgency urinary incontinence (UUI ...

Resonetics said the deal combines its "comprehensive implantable battery technologies with advanced pulse generator ...

The commercial launch of the integrated products provides people with type 1 diabetes a new level of flexibility and personalization in their diabetes management. Pairing twiist™ with Senseonics’ ...

By contrast, the implantable ventilator draws air in, by helping the diaphragm to contract. The implant takes the form of two soft inflatable tubes that lie across the top of the diaphragm on either ...

The implantable lens maker said it would remain a stand-alone company after its shareholders turned down Alcon’s $1.6 billion ...

Series C funding to accelerate the clinical and industrial development of FlowMaker®€48 million in grants from the IPCEI Tech4Cure program to structure the European Active Implantable Medical Devices ...